肾肿块活检与早期肾癌手术减少相关
基于美国国家癌症数据库2004至2015年106258例cT1aN0M0肾细胞癌患者,分析发现肾肿块活检使用率从8.0%升至15.3%,非手术治疗从11.7%升至15.6%。活检与非手术治疗(OR 4.80)及主动监测(OR 1.87)独立相关,且预测概率随年龄和合并症增加。活检患者病理升级(≥pT3a)更常见(5.8% vs 3.3%),调整后OR 1.31。
要点
- 肾肿块活检使用率从8.0%增至15.3%,非手术治疗从11.7%增至15.6%。
- 活检与非手术治疗独立相关(OR 4.80),与主动监测独立相关(OR 1.87)。
- 活检患者病理升级更常见(5.8% vs 3.3%),调整后OR 1.31。
核心结论
- 肾肿块活检与cT1aN0M0肾癌手术减少独立相关,尤其在高龄和合并症多的患者中。
- 活检与病理升级的关联需谨慎解读,但是否影响预后尚不确定。
研究设计与样本
- 回顾性分析美国国家癌症数据库2004至2015年106258例cT1aN0M0肾细胞癌患者。
- 采用多变量logistic回归识别非手术治疗、活检和病理升级的独立关联。
- 按年龄和合并症推导边际效应,并在2010-2015年进行主动监测敏感性分析。
主要发现
- 活检使用率从8.0%升至15.3%,非手术治疗从11.7%升至15.6%。
- 活检与非手术治疗显著相关(OR 4.80 [95%CI 4.58-5.02], P <.001)。
- 敏感性分析中活检与主动监测显著相关(OR 1.87 [1.69-2.07], P <.001)。
- 非手术治疗预测概率范围3%至92%(活检中位31.4%),随年龄和合并症增加。
- 活检患者病理升级(≥pT3a)更常见(5.8% vs 3.3%, P <.001),调整后OR 1.31 [95%CI 1.24-1.38], P <.001。
临床怎么用
- 对cT1aN0M0肾癌患者,尤其高龄或合并症多者,可考虑肾肿块活检以辅助非手术治疗决策。
- 活检后需警惕病理升级可能,但不应仅因此改变治疗选择,需结合预后评估。
局限性
- 回顾性数据库研究,可能存在选择偏倚和未测量混杂。
- 病理升级与预后关系不确定,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether use of renal mass biopsy may be associated with a reduction in surgery for patients with small, localized renal cell carcinoma (cT1aN0M0), especially among older patients and patients with greater comorbidity burden. METHODS: A total of 106,258 patients with cT1aN0M0 renal cell carcinoma from 2004 to 2015 were analyzed in the National Cancer Data Base. Multivariable logistic regression identified independent associations with nonsurgical management, receipt of biopsy, and pathologic upstaging. Marginal effects were derived by age and comorbidity. A sensitivity analysis was conducted in years identifying patients undergoing active surveillance (2010-2015). RESULTS: There was increased use of biopsy (8.0%-15.3%) and nonsurgical management (11.7%-15.6%) over time. Biopsy was significantly associated with use of nonsurgical management (OR 4.80 [95%CI 4.58-5.02], P <.001) as well as active surveillance (OR 1.87 [1.69-2.07], P <.001) in the sensitivity analysis. Individual predicted probability of undergoing nonsurgical management ranged from 3% to 92% (median 31.4% with use of biopsy) and increased with age and comorbidity. Pathologic tumor upstaging (≥pT3a) occurred more frequently for patients receiving biopsy compared to no biopsy (5.8% vs 3.3%, P <.001). After adjustment, biopsy remained a statistically significant predictor of upstaging (OR 1.31 [95%CI 1.24-1.38], P <.001). CONCLUSION: Overall, biopsy demonstrated a strong, independent association with reduced use of surgery for cT1aN0M0 kidney cancer, especially with increasing age and comorbidity. The potential association of renal mass biopsy with upstaging warrants caution, but it is uncertain whether it impacts prognosis relative to true perinephric fat invasion.
引用
- Patel HD, Nichols PE, Su ZT, et al. Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer. Urology. 2019. PMID: 31536739. doi:10.1016/j.urology.2019.08.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。